Evidence map›Paper›PMID 41769870›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

One-Step Glycoengineering of NK Cells With High-Affinity Siglec Ligands for Cancer Immunotherapy.

Shuai Hu, Ben Huang, Lingyan Wang, Qiang Guo, Cuiping Jiang, Ruicheng Qi, Shuyao Wang, Lin-Tai Da, Wenjie Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuai HuKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Ben HuangKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Lingyan WangKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Qiang GuoKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Cuiping JiangKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Ruicheng QiKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Shuyao WangKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Lin-Tai DaKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Wenjie PengKey Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0001-5093-7115

Funding

Medical-Engineering Interdisciplinary Research Foundation of Shanghai Jiao Tong University YG2022ZD001Medical-Engineering Interdisciplinary Research Foundation of Shanghai Jiao Tong University YG2025QNB53National Natural Science Foundation of China 22177069National Natural Science Foundation of China 22577071Natural Science Foundation of Shanghai 23ZR1432500Shanghai Pilot Program for Basic Research-Shanghai Jiao Tong University 21TQ1400210
6 · The paper itself

Abstract

Siglecs, a family of sialic acid (Sia)-binding immunomodulatory receptors selectively expressed on immune cells, are promising immunotherapeutic targets. While synthetic Sia derivatives can manipulate the Sia-Siglec axis with high affinity, their therapeutic application has been hampered by the poor substrate tolerance of wild-type CMP-sialic acid synthase (CSS) for sterically demanding analogs. Here, we report a structure-guided engineering strategy to evolve Neisseria meningitidis CMP-Sia synthetase (NmCSS) for enhanced activity with bulky substrates. Coupling this optimized NmCSS variant with a sialyltransferase enabled a scalable "one-pot two-enzyme" (OPTE) synthesis of diverse sialoside analogs. Screening this library on glycan microarrays revealed novel high-affinity ligands with selective Siglec binding profiles. Leveraging the OPTE system, we achieved single-step glycoengineering of natural killer (NK)-92MI cells with tailored Siglec-2 or Siglec-3 ligands, which exhibited potent cytotoxicity against B-cell lymphoma (Siglec-2

Indexed as

ImmunotherapyKiller Cells, NaturalN-Acylneuraminate CytidylyltransferaseNeoplasmsSialic Acid Binding Immunoglobulin-like LectinsAnimalsHumansLigandsNeisseria meningitidisLigandsN-Acylneuraminate CytidylyltransferaseSialic Acid Binding Immunoglobulin-like Lectinschemoenzymatic glycoengineeringCMP‐sialic acid synthetase evolutioncomputational modellinghigh affinity Siglec ligandsimmunotherapeutic glycan remodeling

Identifiers

PMID41769870
PMCPMC13159100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.